Meckler Amends Indaptus Therapeutics Stake Filing
Ticker: INDP · Form: SC 13D/A · Filed: Nov 26, 2024 · CIK: 1857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | SC 13D/A |
| Filed Date | Nov 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $50,000, $1.175, $1.05 |
| Sentiment | neutral |
Sentiment: neutral
Topics: schedule-13d, amendment, beneficial-ownership
TL;DR
Meckler updated his Indaptus Therapeutics stake filing, watch for changes.
AI Summary
Jeffrey A. Meckler, filing an amendment (No. 1) to Schedule 13D on November 26, 2024, reports changes in beneficial ownership of Indaptus Therapeutics, Inc. common stock. The filing indicates a shift in reporting obligations, potentially due to changes in ownership percentage or other factors requiring a 13D filing instead of a 13G. The company, formerly Intec Parent Inc., is incorporated in Delaware with a fiscal year end of December 31.
Why It Matters
This amendment signals a potential change in the control or influence of Indaptus Therapeutics, Inc. by a significant shareholder, which could impact the company's strategic direction.
Risk Assessment
Risk Level: medium — Schedule 13D filings often indicate significant changes in beneficial ownership, which can precede major corporate events or shifts in control.
Key Players & Entities
- Jeffrey A. Meckler (person) — Filing person and potential beneficial owner
- Indaptus Therapeutics, Inc. (company) — Subject company
- Intec Parent Inc. (company) — Former company name
FAQ
What specific event triggered the amendment to the Schedule 13D filing?
The filing does not explicitly state the specific event that triggered the amendment, only that it is Amendment No. 1 and the date of the event requiring the filing is November 22, 2024.
What was the previous filing status before this Schedule 13D/A?
The filing mentions the possibility of having previously filed a Schedule 13G, indicating a potential transition from a passive to an active reporting status.
What is the business address of Indaptus Therapeutics, Inc.?
The business address is 3 Columbus Circle, 15th Floor, New York, NY 10019.
When did the company change its name from Intec Parent Inc.?
The date of the name change from Intec Parent Inc. was April 14, 2021.
Who is authorized to receive notices and communications for this filing?
Jeffrey A. Meckler, c/o Indaptus Therapeutics, Inc., 3 Columbus Circle, 15th Floor, New York, NY 10019, is the person authorized to receive notices and communications.
Filing Stats: 1,296 words · 5 min read · ~4 pages · Grade level 11.8 · Accepted 2024-11-26 16:11:08
Key Financial Figures
- $0.01 — Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class o
- $50,000 — ggregate consideration of approximately $50,000 using personal funds. Item 4. Purpose
- $1.175 — r Warrants”) for consideration of $1.175 for one share and a warrant to purchase
- $1.05 — rcise price of the November Warrants is $1.05 per share. The November Warrants are im
Filing Documents
- formsc13da.htm (SC 13D/A) — 76KB
- 0001493152-24-047805.txt ( ) — 78KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date : November 26, 2024 By: /s/ Jeffrey A. Meckler Name: Jeffrey A. Meckler